Rytwiński K
Arch Immunol Ther Exp (Warsz). 1979;27(6):819-27.
Donor allogeneic C57Bl/6 lymphoid cells from peritoneal cavity, lymph nodes, thymus and spleen of immunized and non-immunized mice were used for adoptive immunotherapy of L-1210 ascites leukemia in DBA/2J recipients. Donor effector cells were injected i.p. into leukemic mice which were given a whole-body irradiation in a dose of 300 r X-rays prior to leukemia inoculation. The in vitro cytotoxicity of the effector cells was tested by the LT- and 51Cr-tests. Cytokinetics of leukemia undergoing therapy was followed by impulse-cytophotometry. An adoptive chemo-immunotherapy with the aid of peritoneal or splenic lymphoid cells from immunized donors proved to be most effective. The cells were injected on the second day into recipients inoculated with leukemia on the day 0, and then given on the first day a single i.p. injection of cyclophosphamide in a dose of 50 mg/kg body weight. Under these conditions the secondary disease did not influence therapy and apart from a distinctly prolonged survival there was also noted a number of permanent survivals of leukemia. It was also found that peritoneal and splenic lymphoid cells of immunized donors exhibited most pronounced direct and indirect cytotoxicity against target cells in vitro. In vivo, the effector cells mounted an attack on the L-1210 cells probably at the onset of the G1-phase of the cell cycle.
将来自免疫和未免疫小鼠腹腔、淋巴结、胸腺和脾脏的供体同种异体C57Bl/6淋巴细胞用于对DBA/2J受体的L-1210腹水白血病进行过继免疫治疗。将供体效应细胞经腹腔注射到白血病小鼠体内，这些小鼠在接种白血病之前接受了300伦琴X射线的全身照射。通过淋巴细胞毒试验和51铬释放试验检测效应细胞的体外细胞毒性。通过脉冲细胞光度法跟踪正在接受治疗的白血病的细胞动力学。借助来自免疫供体的腹腔或脾脏淋巴细胞进行的过继化学免疫治疗被证明是最有效的。在第0天给受体接种白血病，在第2天给其注射细胞，然后在第1天经腹腔单次注射剂量为50毫克/千克体重的环磷酰胺。在这些条件下，继发性疾病不影响治疗，除了明显延长生存期外，还注意到一些白血病的永久存活情况。还发现，免疫供体的腹腔和脾脏淋巴细胞在体外对靶细胞表现出最明显的直接和间接细胞毒性。在体内，效应细胞可能在细胞周期的G1期开始时对L-1210细胞发起攻击。
